French drugmaker Sanofi-Aventis would not confirm a report in daily Le Figaro on Friday saying it hoped to reach a takeover deal that would value U.S. target Genzyme (GENZ.O) at around $76 per share, or some $20 billion. "The position of the group regarding talks with Genzyme remains that contained in the statement we released on Sunday," a Sanofi-Aventis (SASY.PA) spokesman said. [ID:nLDE7080FM] The total figure would include a cash component of $70 to $71 combined with an earn-out known as a contingent value right (CVR), the Figaro said, citing unnamed sources in the French camp. Sanofi has so far offered $69 a share.
Source
